A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology

References

• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJEfor the Lung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333
   PubMed Web of Science ®Google Scholar
• MartinezFJHanMKFlahertyKCurtisJRole of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary diseaseExpert Rev Anti Infect Ther20064110112416441213
   PubMedGoogle Scholar
• Soler-CatalunaJJMartínez-GarcíaMARomán SánchezPSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• AnzuetoASethiSMartinezFJExacerbations of chronic obstructive pulmonary diseaseProc Am Thorac Soc20074755456417878469
   PubMedGoogle Scholar
• RamseySDHobbsFDChronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular diseaseProc Am Thorac Soc20067363564016963547
   PubMedGoogle Scholar
• NiewoehnerDEThe impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary diseaseAm J Med200611910 Suppl 1S3845
   PubMed Web of Science ®Google Scholar
• LlorCMolinaJNaberanKCotsJMRosFMiravitllesMfor the EVOCA study groupExacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcareInt J Clin Pract200862458559218266710
   PubMed Web of Science ®Google Scholar
• WilkinsonTWedzichaJAStrategies for improving outcomes of COPD exacerbationsInt J Chron Obstruct Pulmon Dis20061333534218046870
   PubMedGoogle Scholar
• DalalAAChristensenLLiuFRiedelAADirect costs of chronic obstructive pulmonary disease among managed care patientsInt J Chron Obstruct Pulmon Dis2010534134921037958
   PubMedGoogle Scholar
• SethiSMurphyTFAcute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology – impact on approaches to risk stratification and therapyInfect Dis Clin North Am200418486188215555829
   PubMed Web of Science ®Google Scholar
• DanielsJMSnijdersDde GraaffCSVlaspolderFJansenHMBoersmaWGAntibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2010181215015719875685
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLHebertPOutpatient oral prednisone after emergency treatment of chronic obstructive pulmonary diseaseN Engl J Med2003348262618262512826636
   PubMed Web of Science ®Google Scholar
• AdamsSGMeloJLutherMAnzuetoAAntibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPDChest200011751345135210807821
   PubMed Web of Science ®Google Scholar
• WoodheadMBlasiFEwigSEuropean Respiratory SocietyEuropean Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infectionsEur Resp J200526611381180
   PubMed Web of Science ®Google Scholar
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for Diagnosis, Management, and Prevention of COPD Available at: http://goldcopd.comAccessed April 4, 2011
   Google Scholar
• DeverLLShashikumarKJohansonWGJrAntibiotics in the treatment of acute exacerbations of chronic bronchitisExpert Opin Investig Drugs2002117911925
   PubMed Web of Science ®Google Scholar
• SethiSAntibiotics in acute exacerbations of chronic bronchitisExpert Rev Anti Infect Ther20108440541720377336
   PubMed Web of Science ®Google Scholar
• MiravitllesMTorresANo more equivalence trials for antibiotics in exacerbations of COPD, pleaseChest2004125381181315006934
   PubMed Web of Science ®Google Scholar
• WilsonRAllegraLHuchonGfor the MOSAIC Study GroupShort- term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitisChest2004125395396415006954
   PubMed Web of Science ®Google Scholar
• AnthonisenNRMaanfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards InstituteMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards8th Edition CLSI document M07-A8Wayne, PA2009
   Google Scholar
• MiravitllesMMoxifloxacin in the management of exacerbations of chronic bronchitis and COPDInt J Chron Obstruct Pulmon Dis20072319120418229559
   PubMedGoogle Scholar
• SethiSBretonJWynneBEfficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitisAntimicrob Agents Chemother200549115316015616290
   PubMed Web of Science ®Google Scholar
• WhiteARKayeCPoupardJAugmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agentJ Antimicrob Chemother200453Suppl 1i3i2014726431
   PubMed Web of Science ®Google Scholar
• Summary of Product CharacteristicsAvelox 400 mg film-coated tabletsBayer Schering PharmaBayer UK Available at: http://www.medicines.org.uk/EMC/medicine/11841/SPC/Avelox+400+mg+film-coated+tabletsAccessed April 4, 2011
   Google Scholar
• JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireRespir Med199185Suppl B2531 discussion 33–371759018
   PubMed Web of Science ®Google Scholar
• JonesPWActivity limitation and quality of life in COPDCOPD20074327327817729072
   PubMedGoogle Scholar
• JonesPWThe Acute Exacerbation of COPD Symptom Scale (AECB-SS)J COPD Management2006 Quarter 2, article 3
   Google Scholar
• Food and Drug AdministrationGuidance for Industry Non-Inferiority Clinical Trials Additional2010 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdfAccessed April 4, 2011
   Google Scholar
• PatelAWilsonRNewer fluoroquinolones in the treatment of acute exacerbations of COPDInt J Chron Obstruct Pulmon Dis20061324325018046861
   PubMedGoogle Scholar
• SiddiqiASethiSOptimizing antibiotic selection in treating COPD exacerbationsInt J Chron Obstruc J Pulmon Dis2008313144
   PubMedGoogle Scholar
• HurstJRDonaldsonGCQuintJKTemporal clustering of exacerbations in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009179536937419074596
   PubMed Web of Science ®Google Scholar
• AnzuetoARizzoJAGrossmanRFThe infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitisClin Infect Dis19992861344134510451195
   PubMed Web of Science ®Google Scholar
• ChodoshSClinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitisChest200512762231223615947342
   PubMed Web of Science ®Google Scholar
• WilsonRJonesPSchabergTfor the MOSAIC Study GroupAntibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitisThorax200661433734216449273
   PubMed Web of Science ®Google Scholar
• MiravitllesMGuerreroTMayordomoCFactors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study GroupRespiration200067549149211185489
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAfor the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsSusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• WedzichaJASeemungalTACOPD exacerbations: defining their cause and preventionLancet2007370958978679617765528
   PubMed Web of Science ®Google Scholar
• PereraWRHurstJRWilkinsonTMInflammatory changes, recovery and recurrence at COPD exacerbationEur Respir J200729352753417107990
   PubMed Web of Science ®Google Scholar
• DewanNARafiqueSKanwarBAcute exacerbation of COPD: factors associated with poor treatment outcomeChest2000117366267110712989
   PubMed Web of Science ®Google Scholar
• WhiteAJGompertzSBayleyDLResolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitisThorax200358868068512885984
   PubMed Web of Science ®Google Scholar
• O’DonnellDEAaronSBourbeauJCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 updateCan Respir J200714Suppl B5B32B
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationGuidance for IndustryAcute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment2008 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070935.pdfAccessed April 4, 2011
   Google Scholar